Physician profile
Afeera A Aabida
NPI 1891993317
$1,339.13
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $258 · 2021: $427.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $247.96 | 2019-2021 | |
| Lilly USA, LLC | $156.14 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $83.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.84 | 2019-2021 | |
| Pfizer INC. | $57.41 | 2019-2021 | |
| Amarin Pharma, INC. | $50.74 | 2019-2020 | |
| Allergan, INC. | $46.00 | 2019 | |
| Amgen INC. | $45.95 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.87 | 2021 | |
| Abbvie INC. | $36.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.76 | 2020-2021 | |
| Eisai INC. | $17.77 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.32 | 2021 | |
| Astellas Pharma US INC | $16.57 | 2019 | |
| Genentech USA, INC. | $16.43 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.95 | 2019 | |
| Celgene Corporation | $12.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afeera Aabida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.